Home » FDA Approves Qiagen’s EGFR Kit As CDx for Lung Cancer Drug
FDA Approves Qiagen’s EGFR Kit As CDx for Lung Cancer Drug
July 19, 2013
The FDA has approved Qiagen’s therascreen EGFR RGQ PCR kit to pinpoint non-small cell lung cancer (NSCLC) patients who may benefit from treatment with Gilotrif. The approval includes the Boehringer Ingelheim drug.